In addition to existing collaboration with top tier biotech companies: Takeda pharmaceutical, Adaptimmune Therapeutics, Autolus Therapeutics, Legend Biotech, Noile-Immune announced that it entered collaboration with Chugai Pharmaceutical on June 04. As a strategic partner, BiGEN sincerely congratulates on the achievement that Noile-Immune has made and will do its best effort to provide meaningful and realistic cell therapy products for patients suffering from devastating diseases together with Noile-immune.
Noile-Immune Biotech Enters Collaboration with Chugai Pharmaceutical
on Technology Assessment
Tokyo, Japan (June 4, 2020) - Noile-Immune Biotech Inc. (“Noile-Immune”) today announced that Noile-Immune and Chugai Pharmaceutical Co., Ltd. (“Chugai Pharmaceutical”) have entered into the agreement regarding PRIME (Proliferation inducing and migration enhancing) technology assessment.
PRIME technology was invented and developed by Dr. Koji Tamada, the scientific founder and the director of Noile-Immune, the professor of Yamaguchi University Graduate School of Medicine. PRIME technology has a capability of not only enhancing the functions of gene-modified immune cells such as CAR-T cells by producing cytokines and chemokines, but also improving the ability of patient's own immune systems to treat cancer. Noile-Immune has the exclusive right to implement PRIME technology.
Under this agreement, Chugai Pharmaceutical will evaluate Noile-Immune’s PRIME technology. Further details of this agreement are not disclosed.